Company: AZN
Filing Date: 2025-09-22
Form Type: 6-K
Source: 0001654954-25-010967
Chunk: 5

Company: ASTRAZENECA PLC
Filing Date: 2025-09-22
Form: 6-K
Chunk 5
---
 & Immunology/World Allergy Organization Joint Congress 2025 (28 February - 03 March).

2. Lipworth, BJ, Han JK, et al. Tezepelumab in adults with severe, uncontrolled CRSwNP. N Engl J Med . 2025;392(12):1178-1188.

3. Bachert C, et al . Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):621-628.

4. Del Toro E, Portela J. Nasal Polyps. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560746/ [Last accessed: September 2025].

5. Stevens WW, et al . Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016;4(4):565-572.

6. Abdalla S, et al . Prevalence of sinonasal outcome test (SNOT-22) symptoms in patients undergoing surgery for chronic rhinosinusitis in the England and Wales National prospective audit. Clin Otolaryngol. 2012;37(4):276-282.

7. Chen S, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897-1911.

8. Viskins A, et al. Multiple reasons underlaying uncontrolled disease in the majority of chronic rhinosinusitis patients. Front Allergy. 2022;13;3:1048385.

9. Tezspire (tezepelumab) US prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761224s003lbl.pdf . [Last accessed: September 2025].

10. Tezspire (tezepelumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.pdf . [Last accessed: September 2025].

11. AstraZeneca news release. Tezspire approved in Japan for